Ning Zhang1, Yifeng Liao2, Weize Lv2, Shunda Zhu3, Yeqing Qiu2, Nan Chen2, Mei Xiao4, Hongyu Zhang5. 1. Internal Medicine Oncology, Minhang Brunch Fudan University Shanghai Cancer Center, Shanghai, 200240, China. 2. Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, China. 3. Department of Neurosurgery, Huizhou Third People's Hospital, Guangzhou Medical University, 516000, Huizhou, China. 4. Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, China. xiaomei@mail.sysu.edu.cn. 5. Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, 519000, China. zhhyu@mail.sysu.edu.cn.
Abstract
BACKGROUND: Phosphohistidine phosphatase 1 (PHPT1) is an oncogene that has been reported to participate in multiple tumorigenic processes. As yet, however, the role of PHPT1 in lung cancer development remains uncharacterized. METHODS: RNA sequencing assay and 18 pairs of tumor and normal tissues from patients were analyzed to reveal the upregulation of PHPT1 in lung cancer, followed by confirming the biological function in vitro and in vivo. Next, Gene Set Enrichment Analysis, lung cancer samples, apoptosis assay, mass spectrometry experiments and western blotting were used to investigate the molecular mechanism underlying PHPT1 driven progression in epidermal growth factor receptor (EGFR)-mutant lung cancer. Finally, we performed cellular and animal experiments to explore the tumor suppressive function of F-box protein 32 (FBXO32). RESULTS: We found that PHPT1 is overexpressed in lung cancer patients and correlates with a poor overall survival. In addition, we found that the expression of PHPT1 is elevated in EGFR-mutant lung cancer cells and primary patient samples. Inhibition of PHPT1 expression in EGFR mutant lung cancer cells significantly decreased their proliferation and clonogenicity, and suppressed their in vitro tumor growth. Mechanistic studies revealed that activation of the ERK/MAPK pathway is driven by PHPT1. PHPT1 is required for maintaining drug resistance to erlotinib in EGFR mutant lung cancer cells. We found that FBXO32 acts as an E3 ubiquitin ligase for PHPT1, and that knockdown of FBXO32 leads to PHPT1 accumulation, activation of the ERK/MAPK pathway and promotion of the proliferation, clonogenicity and growth of lung cancer cells. CONCLUSIONS: Our findings indicate that PHPT1 may serve as a biomarker and therapeutic target for acquired erlotinib resistance in lung cancer patients carrying EGFR mutations.
BACKGROUND: Phosphohistidine phosphatase 1 (PHPT1) is an oncogene that has been reported to participate in multiple tumorigenic processes. As yet, however, the role of PHPT1 in lung cancer development remains uncharacterized. METHODS: RNA sequencing assay and 18 pairs of tumor and normal tissues from patients were analyzed to reveal the upregulation of PHPT1 in lung cancer, followed by confirming the biological function in vitro and in vivo. Next, Gene Set Enrichment Analysis, lung cancer samples, apoptosis assay, mass spectrometry experiments and western blotting were used to investigate the molecular mechanism underlying PHPT1 driven progression in epidermal growth factor receptor (EGFR)-mutant lung cancer. Finally, we performed cellular and animal experiments to explore the tumor suppressive function of F-box protein 32 (FBXO32). RESULTS: We found that PHPT1 is overexpressed in lung cancer patients and correlates with a poor overall survival. In addition, we found that the expression of PHPT1 is elevated in EGFR-mutant lung cancer cells and primary patient samples. Inhibition of PHPT1 expression in EGFR mutant lung cancer cells significantly decreased their proliferation and clonogenicity, and suppressed their in vitro tumor growth. Mechanistic studies revealed that activation of the ERK/MAPK pathway is driven by PHPT1. PHPT1 is required for maintaining drug resistance to erlotinib in EGFR mutant lung cancer cells. We found that FBXO32 acts as an E3 ubiquitin ligase for PHPT1, and that knockdown of FBXO32 leads to PHPT1 accumulation, activation of the ERK/MAPK pathway and promotion of the proliferation, clonogenicity and growth of lung cancer cells. CONCLUSIONS: Our findings indicate that PHPT1 may serve as a biomarker and therapeutic target for acquired erlotinib resistance in lung cancer patients carrying EGFR mutations.
Authors: Robert A Smith; Kimberly S Andrews; Durado Brooks; Stacey A Fedewa; Deana Manassaram-Baptiste; Debbie Saslow; Otis W Brawley; Richard C Wender Journal: CA Cancer J Clin Date: 2018-05-30 Impact factor: 508.702
Authors: Jason D Merker; Geoffrey R Oxnard; Carolyn Compton; Maximilian Diehn; Patricia Hurley; Alexander J Lazar; Neal Lindeman; Christina M Lockwood; Alex J Rai; Richard L Schilsky; Apostolia M Tsimberidou; Patricia Vasalos; Brooke L Billman; Thomas K Oliver; Suanna S Bruinooge; Daniel F Hayes; Nicholas C Turner Journal: J Clin Oncol Date: 2018-03-05 Impact factor: 44.544
Authors: Pierre P Massion; Graham F Healey; Laura J Peek; Lynn Fredericks; Herb F Sewell; Andrea Murray; John F R Robertson Journal: J Thorac Oncol Date: 2016-09-08 Impact factor: 15.609